Table 3 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
收藏数据链接：
官方服务：
资源简介：
Summary of DLT by system organ class and preferred term (all causalities). DLT—evaluable analysis set.
创建时间：
2025-07-15
